Merge Healthcare Incorporated (NASDAQ: MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, today announced that Datapharm Australia Pty Ltd. has selected Merge’s eClinicalOS® solution to bring EDC in-house and provide control of electronic case report form (eCRF) creation and mid-study adjustments.
“We’ve seen an increase in the number of our clients’ studies requiring EDC. Previously, we outsourced EDC projects to a third party vendor to handle eCRF setup,” explained Dr. Helen Allars, Managing Director at Datapharm Australia. “We found that we spent more time and resources managing this process and dealing with support issues. This approach also lacked the flexibility and control for mid-study changes.”
In 2010, Datapharm began an extensive EDC vendor evaluation, which included 14 vendors who could offer in-licensing of software for use across an enterprise, also referred to as technology transfer. Datapharm’s evaluation criteria consisted of a comprehensive suite of EDC tools, time to deployment, and overall costs associated with technology transfer.
“eClinicalOS provided all the EDC features we needed – such as 21 CFR Part 11 and CDISC compliance, Hybrid/DDE, CRF library, reporting, data upload and exporting, medical coding, and monitoring tools – as well the opportunity to add patient reported outcomes, interactive response, randomization and inventory management if a particular study called for it,” continued Allars. “We were most impressed with how intuitive and flexible the system is, whether we are creating eCRFs or even making mid-study changes.”
“Companies that are bringing our solution in-house are doing so because they recognize that eClinicalOS provides a strategic tool in their pursuit to provide more efficient, cost-effective clinical trials services,” said Justin Dearborn, President of Merge Healthcare. “Datapharm has taken the first critical step to yield the greatest efficiencies and financial rewards of using our eClinical technologies to simplify and accelerate the way they perform clinical trials.”
Merge eClinicalOS is a unified platform delivering end-to-end study support. Clinical trial capabilities can be mixed and matched to build a solid foundation for each trial environment, and features and services can be added as needed, directly from within the system. As a single, web-based solution, it has the flexibility to support trials in any phase, and captures any type of data, from any source, over any modality. Merge eClinicalOS also has the scalability to grow if a trial increases in size, number or complexity.
About Merge Healthcare
Merge is a leading provider of clinical systems and innovations that seek to transform healthcare. Merge’s enterprise and cloud-based solutions for image intensive specialties provide access to any image, anywhere, any time. Merge also provides health stations, clinical trials software and other health data and analytics solutions that engage consumers in their personal health. With solutions that are used by providers and consumers and include more than 20 years of innovation, Merge is helping to reduce costs and improve the quality of healthcare worldwide. For more information, visit merge.com.
About Datapharm Australia
Datapharm Australia is Australia’s most experienced Full Service Contract Research Organization (CRO), celebrating 25 years in 2012. Services include: clinical trial management, set-up, monitoring, data management, statistical analysis and programming, medical writing, pharmacovigilance and auditing for Phase I to IV studies in over 35 therapeutic areas since 1987. Datapharm aims to provide clients with the best cost-effective, quality outcomes. For more information, visit DatapharmAustralia.com.
Cautionary Notice Regarding Forward-Looking Statements
The matters discussed in this news release may include forward-looking statements, which could involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, such forward-looking statements. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements.